MERCK & CO, INC. for MERCK & CO INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill); R&D tax credit (no specific bill).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI JOSEPH | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Health Issues HCR
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Copyright/Patent/Trademark CPT
Patent reform (H.R. 3309, S. 1720 )
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Animals ANI
education on beta-agonists (no specific bills)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN POLAK | — |
Trade (domestic/foreign) TRD
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Medicare/Medicaid MMM
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Budget/Appropriations BUD
Deficit reduction (no specific bill); ADAP funding (no specific bill); omnibus appropriations...
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| ELI JOSEPH | — |
| JEROME MURRAY | — |
| KATIE OPPENHEIM | — |
| ERIN POLAK | — |
| ANGELA M STEWART | — |
| JASON BENJAMIN VAN PELT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.